For those seeking effective weight loss options, there are several therapies available that have shown promising results. These therapies include Tirzepatide, Semaglutide, AOD 9604, Tesofensine, 5 Amino 1MQ, and MOTS-C.
Tirzepatide
Tirzepatide stands out as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 agonist.
Recent studies have explored its potential as a treatment for noncirrhotic NASH (nonalcoholic steatohepatitis) patients due to its significant association with weight loss and improvements in metabolic syndrome features observed in diabetes trials.
Combining GIP and GLP-1, which antagonizes some of the central effects of GLP-1 to prevent nausea, enhances tolerability and allows for more aggressive dosing. Research has shown decreased NASH-related biomarkers and increased adiponectin in patients with Type 2 diabetes. Moreover, GIPR antagonism, with possible metabolic benefits, raises the possibility of developing GIPR antagonist: GLP-1R agonist combinations to address obesity and Type 2 diabetes.
Semaglutide
Semaglutide is the first FDA-approved GLP-1 receptor agonist for chronically obese adults with weight-related illnesses such as type 2 diabetes, hypertension, and abnormal lipid profiles. It has demonstrated its effectiveness in promoting weight loss through appetite and hunger suppression, reducing energy intake, and controlling eating habits. Clinical trials have shown substantial weight reduction in both obese children and adults, and it is available in subcutaneous and oral formulations.
AOD 9604 (Anti-Obesity Drug)
AOD 9604, known as the “Anti-Obesity Drug,” is designed to help individuals burn excess fat and achieve their weight loss goals. It is a modified fragment of human growth hormone (HGH) that targets the pituitary gland, speeding up metabolism. Those who use AOD 9604 report significant weight loss when included in their weight loss regimen. This peptide is considered more effective at burning fat compared to diet and exercise alone, with minimal reported side effects and recognition by the FDA.
Tesofensine
Tesofensine is categorized as a presynaptic serotonin–noradrenaline–dopamine reuptake inhibitor. By preventing the reabsorption of these neurotransmitters in the central nervous system, it acts as an appetite suppressant, promotes fat oxidation, and increases resting energy expenditure. Tesofensine was initially developed for neurological conditions like Alzheimer’s and Parkinson’s but was later repurposed for obesity treatment due to consistent reports of weight loss as an adverse event in the original studies.
5 Amino 1MQ Peptide
5-amino-1MQ is a molecule that inhibits the activity of NNMT, an enzyme that regulates cell energy balance and fat tissue. NNMT slows down fat cell metabolism, making it challenging for cells to burn fat, and generates more hormones and inflammatory signals. 5 amino 1MQ increases nicotinamide adenine dinucleotide (NAD+), enhancing metabolic rate and potentially shrinking fat cells.
MOTS-C Peptide
MOTS-C is a 16-amino acid peptide expressed by a mitochondrial gene that regulates metabolic functions throughout the body, including glucose utilization and energy production. Preliminary studies suggest its effectiveness in improving blood sugar control for individuals with type 2 diabetes and obesity. MOTS-C is referred to as an exercise-mimetic, mimicking the effects of exercise by activating the AMPK pathway and enhancing insulin sensitivity.
In summary, these therapies offer a range of approaches to weight loss and metabolic improvements, each with its unique mechanisms and potential benefits. Consultation with a healthcare professional is recommended to determine which therapy may be most suitable for individual weight loss goals and health considerations.